Fate Therapeutics Inc at Jefferies Healthcare Conference Transcript
Welcome, everyone. Thank you for joining us on another great afternoon session here at the Jefferies Healthcare Conference. Up here on the stage with us for another great fireside chat is the President and CEO of Fate Therapeutics, Scott Wolchko.
Scott, it has been an interesting journey over the last couple of years, but importantly, a lot of learnings on NK biology, cell therapy, and so many things going on, I would love to just maybe offer you the opportunity to briefly give us a snapshot of Fate as it stands here today in the middle of 2023, had a reset with the pipeline.
Questions & Answers
You actually had an announcement earlier this morning about a new NK program that just saw the IND. So that's going to be in stream. But like Wall Street has been pretty confused about the potential for NK cell therapy. And you've been pioneering the way, then had some disappointments. So where do we stand today with Fate and with your pipeline? And why should we be excited today on Fate?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |